---
title: "Lysergide (DT120) in Generalized anxiety disorder: Dosage forms and strengths"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Dosage forms and strengths. Topics: Phase 3 dosage form: orally disintegrating tablet using Zydis technology; Strengths studied in phase 3: 100 µg, and 50 µg as a control arm in Panorama; Strengths studied in phase 2b: 25, 50, 100, and 200 µg freebase equivalent; Phase 1 bridging study: four 25-µg capsules compared with one 100-µg orally disintegrating tablet; 1 further topic. 5 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/dosage-forms-and-strengths"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Dosage forms and strengths

<a id="heading-2.1.2.2"></a>

## 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

### Phase 3 dosage form: orally disintegrating tablet using Zydis technology

> “DT120 ODT is an advanced formulation incorporating Catalent's Zydis® ODT fast-dissolve technology, designed to deliver several unique advantages, including faster absorption and onset of transient cognitive, perceptual, and affective changes, improved bioavailability, and a lower incidence of gastrointestinal side effects.”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

> “Zydis ODT is a unique, freeze-dried, oral solid dosage form that disperses almost instantly in the mouth, without the need for water.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.2-2"></a>

### Strengths studied in phase 3: 100 µg, and 50 µg as a control arm in Panorama

> “Eligible participants were randomized 2:1:2 to receive a single dose of DT120 ODT 100 µg, DT120 ODT 50 µg, or matching placebo, with the 50 µg arm included to help mitigate functional unblinding.”
> “during which participants may be eligible to receive up to four additional doses of DT120 ODT 100 μg based on symptom severity”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “Voyage is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a single 100 µg dose of DT120 ODT versus placebo in adults with generalized anxiety disorder (GAD).”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.2-3"></a>

### Strengths studied in phase 2b: 25, 50, 100, and 200 µg freebase equivalent

> “Participants were randomized to receive a single (freebase equivalent) treatment dose with 25 µg (n = 39), 50 µg (n = 40), 100 µg (n = 40), or 200 µg (n = 40) of MM120 or placebo (n = 39).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.2-4"></a>

### Phase 1 bridging study: four 25-µg capsules compared with one 100-µg orally disintegrating tablet

> “This phase 1 study compared the pharmacokinetic (PK), subjective effect, and safety profiles of the phase 2b capsule formulation at 100µg with a new 100µg orally disintegrating tablet (ODT) formulation that was subsequently included in the phase 3 program.”
> “Participants were randomized equally to receive either four 25-μg MM120 capsules followed by 100μg MM120 ODT or ODT followed by capsules.”
> “Considering the efficacy and safety profile observed in the phase 2b study, MM120 100μg (freebase-equivalent) is considered an acceptable therapeutic dose.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-2.1.2.2-5"></a>

### Salt form: lysergide D-tartrate

> “Definium is developing DT120 ODT, the tartrate salt form of lysergide, for generalized anxiety disorder (GAD), major depressive disorder (MDD), and posttraumatic stress disorder (PTSD), and is exploring its potential applications in other serious brain health disorders.”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-2.1.2.2-6"></a>

### Commercial dosage form, strengths, and package configuration

No evidence found.

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
